Search

Protagonist Therapeutics Inc

Closed

SectorHealthcare

133.32 1.98

Overview

Share price change

24h

Current

Min

128.41

Max

131.59

Key metrics

By Trading Economics

Income

-82M

3.8M

Sales

49M

56M

P/E

Sector Avg

131.197

60.149

EPS

0.05

Profit margin

6.711

Employees

131

EBITDA

46M

2.7M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

-4.1% downside

Dividends

By Acuity

Next Earnings

4 sie 2026

Market Stats

By TradingEconomics

Market Cap

2.1B

8.5B

Previous open

131.34

Previous close

133.32

News Sentiment

By Acuity

50%

50%

172 / 342 Ranking in Healthcare

Protagonist Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 lip 2026, 23:46 UTC

News

PayPal Holdings Inc. shares are lower in after-market trading despite expanding buy now, pay later options in the UK with a new Pay in 30 Days feature.

14 lip 2026, 23:41 UTC

Event
News

Biogen Inc shares are higher in after-market trading following positive Phase 2 CELIA study results for diranersen, which targets tau in early Alzheimer's disease.

14 lip 2026, 23:32 UTC

Social Media
News

Advanced Micro Devices shares rose in after-market hours following price target increases by analysts, including KeyBanc's $725 target amid strong demand for EPYC processors.

14 lip 2026, 23:32 UTC

News
Social Media

Micron Technology's stock rose in after-market trading following a lower-than-expected inflation report and positive sentiment from IBM regarding memory chip demand.

14 lip 2026, 23:31 UTC

News
Social Media

Amazon.com Inc shares are higher in after-market trading amid positive sentiment. Analysts maintain a bullish outlook on the company's long-term investment strategy.

14 lip 2026, 23:31 UTC

News

Netflix shares are higher in after-hours trading, buoyed by investor confidence despite rising subscription costs and regulatory scrutiny amid broader positive market sentiment.

14 lip 2026, 23:31 UTC

News
Social Media

Alphabet Inc signed a fixed-price power purchase agreement for its largest solar-plus-storage project in the U.S. Shares are lower in after-market hours.

14 lip 2026, 23:31 UTC

News
Correlated Moves

Apple Inc. shares were little changed after KeyBanc downgraded the rating to Sell with a price target of $250. OpenAI countered Apple's trade secret lawsuit claims.

14 lip 2026, 23:11 UTC

News

The Australian Dollar is trading higher against the Singapore Dollar, supported by rising crude oil prices and improved U.S. inflation data.

14 lip 2026, 23:06 UTC

News

Fiserv Inc. will release its second-quarter earnings on August 6, 2026, with shares trading higher in after-market hours amid positive sentiment.

14 lip 2026, 23:06 UTC

News

Workday Inc. shares declined slightly in after-market trading following a challenging year, despite reporting 14.7% year-over-year growth in subscription revenue.

14 lip 2026, 23:06 UTC

Macro News
News
Correlated Moves
ETF Constituents

Health Care Select Sector SPDR Fund is trading higher after proposed Medicare reforms by CMS and Anthem's new Alzheimer's testing coverage announcement.

14 lip 2026, 23:06 UTC

News

United States Oil Fund LP trades higher in after-market hours as Iran withdraws from its agreement with the U.S., raising oil supply stability concerns.

14 lip 2026, 23:01 UTC

News

Cintas Corp is higher in after-market trading, with its market capitalization surpassing Target Corp, positioning it 193rd in the S&P 500.

14 lip 2026, 22:32 UTC

Correlated Moves
News

Geopolitical tensions and rising crude oil prices have contributed to an increase in CHF/HKD since Monday's close, reflecting broader market sentiment.

14 lip 2026, 20:52 UTC

Correlated Moves
News

Vanguard Total Bond Market ETF advances in after-hours trading following a significant drop in the U.S. Consumer Price Index, easing inflation concerns and boosting Treasury demand.

14 lip 2026, 20:07 UTC

News
Social Media

eBay shares are lower amid mixed analyst ratings and social media concerns about growth metrics. Jefferies raised the price target to $75 while maintaining an Underperform rating.

14 lip 2026, 20:07 UTC

News

Xcel Energy shares are lower amid a settlement proposal for a $123 million revenue increase, with regulatory hearings scheduled for July 2026.

14 lip 2026, 20:07 UTC

Social Media
Correlated Moves
News
Macro Event

Gold prices rose sharply today, with August futures reaching $4,092 an ounce after cooler CPI data. SPDR Gold Shares also benefited from this upward trend.

14 lip 2026, 20:07 UTC

News
Social Media

Electronic Arts is set to launch EA Sports Madden NFL 27 Arcade Edition on August 6, contributing to positive investor sentiment as shares trade higher.

14 lip 2026, 20:02 UTC

News
Macro Event

American Airlines shares are lower amid mixed options sentiment and elevated trading volume. The stock is set to report earnings on July 23.

14 lip 2026, 20:02 UTC

Correlated Moves
News

Intuitive Surgical shares are lower as Baird cuts price target to $525 from $610. The stock has reached a 25-month low at $395.02.

14 lip 2026, 20:02 UTC

News
Macro Event

Take-Two Interactive shares are trading lower amid recent inflation data, despite earlier gains during the session reflecting broader market pressures in the gaming sector.

14 lip 2026, 19:56 UTC

News

Citigroup maintained its Buy rating on Monster Beverage and raised the price target to $113, contributing to a higher stock price since Monday's close.

14 lip 2026, 19:52 UTC

Correlated Moves
ETF Constituents
News

Fitch affirmed Canada's credit rating at AA+, boosting sentiment for Canadian assets. The iShares MSCI Canada ETF is trading higher, supported by favorable USD/CAD movement.

14 lip 2026, 19:52 UTC

Macro Event
News

NTAL launched to amplify daily participation in NTAP amid strong activity.

14 lip 2026, 19:46 UTC

News

Marriott International shares rise amid positive sentiment from a new collaboration between The Ritz-Carlton and MERIT Beauty, with Macquarie raising its price target to $365.

14 lip 2026, 19:45 UTC

News
Correlated Moves

Intuit Inc. shares are lower amid a class action lawsuit alleging securities fraud and an investigation into potential violations of federal securities laws.

14 lip 2026, 19:41 UTC

Correlated Moves
Macro Event
News

U.S. CPI showed a month-over-month decrease, boosting demand for Treasury bonds. The iShares 20+ Year Treasury Bond ETF remains higher than Monday's close.

14 lip 2026, 19:37 UTC

News
Social Media

KeyBanc maintains Overweight rating on Intel, raising price target to $155. Strong demand for AI-driven CPUs and improved yields support upward movement in shares today.

Peer Comparison

Price change

Protagonist Therapeutics Inc Forecast

Price Target

By TipRanks

-4.1% downside

12 Months Forecast

Average 124.56 USD  -4.1%

High 151 USD

Low 100 USD

Based on 9 Wall Street analysts offering 12 month price targets forProtagonist Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

8

Buy

1

Hold

0

Sell

Sentiment

By Acuity

172 / 342 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
help-icon Live chat